UBS Group’s Frazier Lifesciences Acquisition Corporation Unit FLACU Stock Holding History

UBS Group’s Portfolio FLACU Stock Details FLACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-773	Closed	-$8K	–	11817
2022 Q3	$8K	Sell	773 -5,110	-87%	-$51.5K	﹤0.01%	8821
2022 Q2	$58K	Buy	5,883 +4,620	+366%	+$45.8K	﹤0.01%	5805
2022 Q1	$12K	Buy	1,263 +175	+16%	+$1.74K	﹤0.01%	8262
2021 Q4	$11K	Buy	1,088 +509	+88%	+$5.1K	﹤0.01%	8725
2021 Q3	$6K	Buy	579 +294	+103%	+$2.95K	﹤0.01%	8490
2021 Q2	$3K	Sell	285 -1,714	-86%	-$17.4K	﹤0.01%	8886
2021 Q1	$20K	Buy	+1,999	New	+$21.3K	﹤0.01%	7413

UBS Group's FLACU Position: Q4 2022 in Review

UBS Group sold out of Frazier Lifesciences Acquisition Corporation Unit (FLACU) in Q4 2022, closing a stake of 773 shares — an estimated $8K sold.

UBS Group first reported a position in FLACU in Q1 2021 and held it in 7 quarters. The position peaked at $58K in Q2 2022. 0 funds tracked by Wall St. Rank hold FLACU as of Q4 2022.

UBS Group reported no remaining Frazier Lifesciences Acquisition Corporation Unit position as of Q4 2022 after selling out during the quarter.
UBS Group sold 773 Frazier Lifesciences Acquisition Corporation Unit shares in Q4 2022, an estimated $8K.
UBS Group first reported a position in Frazier Lifesciences Acquisition Corporation Unit in Q1 2021 and held it in 7 quarters.
UBS Group's Frazier Lifesciences Acquisition Corporation Unit position peaked at $58K in Q2 2022.
0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Unit as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.